Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OKYO Pharma LtdOKYO · Entity 6916 | Chief Scientific Officer | July 27, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OKYO Pharma Ltd
Report date July 27, 2026 · Filed August 07, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 20,030 |
Reported balance
After 2026-07-27 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-07-27 · Purchase · Acquired 3,363 · Balance 20,030 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 20:45 UTC | OKYO Pharma Ltd OKYO · Entity 6916 | GrantCOMMON STOCK | 3,363 | $1.49 | $5,010.87 |
DisclosureSEC source: 0001493152-26-035212 · ownership.xml · nonDerivative · entry 1 Patil Rajkumar V. · CIK 0002124067 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,030 Read SEC document |
| July 27, 2026 Filed Aug 7, 2026 20:15 UTC Amendment | OKYO Pharma Ltd OKYO · Entity 6916 | PurchaseCOMMON STOCK | 3,363 | $1.49 | $5,010.87 |
DisclosureSEC source: 0001493152-26-036581 · ownership.xml · nonDerivative · entry 1 Patil Rajkumar V. · CIK 0002124067 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,030 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.